BioCentury
ARTICLE | Clinical News

VitaResc begins Phase III

May 24, 2001 7:00 AM UTC

VitaResc Biotech (Martinsried, Germany) began an international Phase III trial of its VTR-PHP pyridoxalated hemoglobin polyoxyethylene conjugate to treat nitric oxide (NO)-induced shock, a failure of ...